Niccolo Mencacci is a Neurology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
259 E Erie St Ste 1900
Chicago, IL 606113246
Telephone
312-695-7950Provider last certified this registry record 22 Feb 2021.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- MDD US Operations, LLCProgram year20241 payment
- ACADIA Pharmaceuticals IncProgram year20231 payment
- Merz Pharmaceuticals, LLCProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
87.4%Aromatic Amino Acid Decarboxylation Inhibitor52.9%Carbidopa-Levodopa93%Carbidopa-Levodopa Er7%Part D<11 patientsGabapentinoids7.7%Gabapentin100%Part D<11 patients+ 4 more classes in this area
Cardiovascular
12.6%Beta blocker12.6%Propranolol Hcl57%Propranolol Hcl Er44%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- Understanding the role of BORCS5 in neuronal lysosomal function and neurodegeneration
Northwestern University
FY2026$228,015K08NS131581 - Understanding the role of BORCS5 in neuronal lysosomal function and neurodegeneration
Northwestern University
FY2025$228,015K08NS131581 - Understanding the role of BORCS5 in neuronal lysosomal function and neurodegeneration
Northwestern University at Chicago
FY2024$216,963K08NS131581
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”